Canaccord Genuity Maintains Buy on TransMedics Gr, Raises Price Target to $117
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Jason Mills maintains a Buy rating on TransMedics Group (TMDX) and raises the price target from $102 to $117.
May 01, 2024 | 6:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Group's stock rating was maintained as Buy by Canaccord Genuity, with the price target increased from $102 to $117.
The increase in price target by Canaccord Genuity reflects a positive outlook on TransMedics Group's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100